We confirmed that BEZ235 treatment for 6 h effectively inhibited activities of PI3K/mTOR effectors as assessed by reduced p-AKT S473, p-S6 and p-4E-BP1 levels compared with control treatment (Figure 6a), whereas Bay 65–1942 treatment consistently reduced CXCL1, CXCL2 and CXCL8 mRNA levels in all three ovarian cancer cell lines tested (Figure 6b). This evidence concerns the gene CXCL8 and ovarian carcinoma.